08:59 AM EDT, 09/26/2024 (MT Newswires) -- PTC Therapeutics ( PTCT ) said Thursday its PTC518 program for the treatment of Huntington's disease has received fast track designation from the US Food and Drug Administration.

The biopharmaceutical company reported in June positive results from a 12-month readout of a study evaluating PTC518 in Huntington's disease patients.

Shares were up more than 2% in recent premarket activity.

Price: 37.52, Change: +0.88, Percent Change: +2.40